Spero Therapeutics (NASDAQ:SPRO) Given “Buy” Rating at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Spero Therapeutics (NASDAQ:SPRO) in a research note published on Thursday, Benzinga reports. HC Wainwright currently has a $7.00 price objective on the stock.

Several other research analysts have also recently weighed in on the stock. Cantor Fitzgerald restated an overweight rating on shares of Spero Therapeutics in a research report on Tuesday, August 6th. TD Cowen raised shares of Spero Therapeutics from a hold rating to a buy rating in a report on Tuesday, August 6th.

Spero Therapeutics Stock Performance

Spero Therapeutics stock opened at $1.30 on Thursday. The business’s 50-day simple moving average is $1.32 and its 200-day simple moving average is $1.43. The firm has a market capitalization of $70.19 million, a PE ratio of 3.02 and a beta of 0.62. Spero Therapeutics has a 52 week low of $0.99 and a 52 week high of $1.89.

Spero Therapeutics (NASDAQ:SPRO) last released its earnings results on Monday, August 5th. The company reported ($0.33) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.34) by $0.01. The business had revenue of $10.20 million for the quarter, compared to the consensus estimate of $9.80 million. Spero Therapeutics had a return on equity of 25.67% and a net margin of 14.74%. During the same period last year, the business earned ($0.23) earnings per share. Research analysts forecast that Spero Therapeutics will post -1.59 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the business. Vanguard Group Inc. grew its holdings in shares of Spero Therapeutics by 0.6% during the first quarter. Vanguard Group Inc. now owns 1,653,432 shares of the company’s stock valued at $2,844,000 after buying an additional 9,675 shares during the last quarter. Acadian Asset Management LLC lifted its stake in Spero Therapeutics by 40.6% in the 2nd quarter. Acadian Asset Management LLC now owns 1,071,860 shares of the company’s stock worth $1,392,000 after purchasing an additional 309,262 shares in the last quarter. ADAR1 Capital Management LLC purchased a new stake in shares of Spero Therapeutics during the 4th quarter valued at $1,570,000. Renaissance Technologies LLC grew its holdings in shares of Spero Therapeutics by 14.2% during the 2nd quarter. Renaissance Technologies LLC now owns 975,952 shares of the company’s stock valued at $1,269,000 after purchasing an additional 121,492 shares during the last quarter. Finally, Murchinson Ltd. grew its holdings in shares of Spero Therapeutics by 1.3% during the 1st quarter. Murchinson Ltd. now owns 873,910 shares of the company’s stock valued at $1,503,000 after purchasing an additional 11,210 shares during the last quarter. 25.60% of the stock is owned by institutional investors.

Spero Therapeutics Company Profile

Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease.